bluuebunny/crossref_metadata_2025_split huggingface dataset:
‘Beats the alternative but it messes up your life’: Aboriginal people's experience of haemodialysis in rural Australia
Authors: Rix Elizabeth F , Barclay Lesley , Stirling Janelle , Tong Allison , Wilson Shawn 
Published: September 2014

ObjectivesAustralian Aboriginal people have at least eight times the incidence of end-stage kidney disease, requiring dialysis, as the non-Aboriginal population. Provision of health services to rural Aboriginal people with renal disease is challenging due to barriers to access and cultural differences. We aimed to describe the experiences of Aboriginal people receiving haemodialysis in rural Australia, to inform strategies for improving renal services.DesignA qualitative design incorporating: Indigenist research methodology and Community Based Participatory Research principles. In-depth interviews used a ‘yarning’ and storytelling approach. Thematic analysis was undertaken and verified by an Aboriginal Community Reference Group.SettingA health district in rural New South Wales, Australia.ParticipantsSnowball sampling recruited 18 Aboriginal haemodialysis recipients.ResultsSix themes emerged which described the patient journey: ‘The biggest shock of me life,’ expressed the shock of diagnosis and starting the dialysis; ‘Beats the alternative but it messes up your life,’ explained how positive attitudes to treatment develop; ‘Family is everything’, described the motivation and support to continue dialysis; ‘If I had one of them nurses at home to help me’, depicted acute hospital settings as culturally unsafe; ‘Don't use them big jawbreakers’, urged service providers to use simple language and cultural awareness; ‘Stop ‘em following us onto the machine’, emphasised the desire for education for the younger generations about preventing kidney disease. An Aboriginal interpretation of this experience, linked to the analysis, was depicted in the form of an Aboriginal painting.ConclusionsFamily enables Aboriginal people to endure haemodialysis. Patients believe that priorities for improving services include family-centred and culturally accommodating healthcare systems; and improving access to early screening of kidney disease. Inclusion of Aboriginal patients in cultural education for renal staff is recommended. Providing opportunities for patients to educate young Aboriginal people about kidney disease prevention may be highly effective and empowering.
Prognostic values of highly sensitive cardiac troponin T and B-type natriuretic peptide for clinical features in hypertrophic obstructive cardiomyopathy: a cross-sectional study
Authors: Nakamura Shunichi , Takano Hitoshi , Matsuda Junya , Chinen Daigo , Kitamura Mitsunobu , Murai Koji , Asai Kuniya , Yasutake Masahiro , Takayama Morimasa , Shimizu Wataru 
Published: September 2014

ObjectivesAlthough B-type natriuretic peptide (BNP) and highly sensitive cardiac troponin T (cTnT) are useful for the evaluation of clinical features in various cardiovascular diseases, there are comparatively few data regarding the utility of these parameters in patients with hypertrophic obstructive cardiomyopathy (HOCM). The goal of this study was to assess the association between BNP, cTnT and clinical parameters in patients with HOCM.DesignCross-sectional surveySettingsThe relationship between BNP, cTnT and clinical end points and echocardiographic data was investigated.ParticipantsThis study included 102 consecutive outpatients with HOCM who were clinically stable.ResultsBNP was significantly associated with both maximum left ventricular (LV) wall thickness (r=0.28; p=0.003), and septal peak early transmitral filling velocity/peak early diastolic mitral annulus velocity (r=0.51; p=0.0001). No statistically significant associations were seen between cTnT and any echocardiographic parameters, but the presence of atrial fibrillation (AF) was associated with a high level of cTnT (p=0.01).ConclusionsBNP is useful for monitoring clinical parameters and as a reflection of both LV systolic/diastolic function and increased LV pressure in patients with HOCM. A high level of serum cTnT is associated with the presence of AF.
DESIGN, IMPLEMENTATION AND TESTING OF A FLEXIBLE FULLY-DIGITAL TRANSPONDER FOR LOW-EARTH ORBIT SATELLITE COMMUNICATIONS
Authors: DAVALLE DANIELE , CASSETTARI RICCARDO , SAPONARA SERGIO , FANUCCI LUCA , CUCCHI LUCA , BIGONGIARI FRANCO , ERRICO WALTER 
Published: September 2014

This paper presents a flexible Telemetry, Tracking & Command (TT&C) transponder for Earth Observation (EO) small satellites. The proposed device adds to the state-of-the-art EO TT&C transponders the possibility of scientific data transfer thanks to the high downlink data-rate (up to 40 Mbps) and in-flight reconfigurability via Telecomand (TC). The integration of these features in one single device represents a considerable optimization in terms of mass budget, which is important for EO small satellites. Furthermore, in-flight reconfigurability of communication parameters via TC is important for in-orbit link optimization, which is especially useful for Low-Earth Orbit (LEO) satellites where visibility can be as short as few hundreds of seconds. The proposed transponder is a digital radio unit working at 70 MHz intermediate frequency (IF). A new custom and configurable hardware accelerator was developed to cover intensive radio DSP functions at IF. The custom hardware is integrated in a single FPGA with a space-compliant processor core, for control, configuration and interface with the other satellite subsystems. All the quantization parameters were fine-tailored to reach a trade-off between hardware complexity and implementation loss (IL). The IF RX/TX ports require eight bits and seven bits, respectively. The IL is 0.5 dB at BER = 10-5 for the RX chain. A system proof-of-concept was implemented on the Xilinx Virtex 6 VLX75T-FF484 FPGA. The total device occupation is 82%. The power consumption of the design fitted in FPGA is less than 2 W. The power consumption of the whole demonstrator board is less than 9 W.
Coincidence Measurements in Dual-Color Confocal Microscopy: A Combined Single-Particle and Fluorescence Correlation Approach
Authors: Friaa Ouided , Fradin Cécile 
Published: September 2014

In this paper we discuss how the coincident detection of mobile particles in dual-color confocal images can be improved. Optimal coincidence detection requires a careful choice of experimental conditions and image acquisition parameters in order to maximize the overlap between the two detection volumes. By measuring this overlap with fluorescence cross-correlation spectroscopy, we show in particular that a small confocal field of view is necessary in order to maintain good coincidence. Most importantly, coincidence detection also requires a dedicated image analysis strategy. Traditionally, two approaches have been adopted to assess coincidence of mobile particles: fluorescence fluctuation measurements, notably cross-correlation spectroscopy, and single particle detection. Here we propose to combine these two approaches by calculating a cross-correlation coefficient for each of the detected single particles. We show that this allows to remove accidental coincidence events from a data set, and thus to unambiguously identify particles that instead carry two different fluorophores. This strategy can help increase the available concentration range for confocal coincidence measurements and detect rare binding events. [Formula: see text]Special Issue Comments: This article about coincident detection of mobile particle in two-color confocal images is thematically related to several articles in this Special Issue, namely the review of FRET-based single-molecule fluorescence techniques by Ruedas-Rama et al.,1 the single particle detection work presented by de Keersmaecker et al.2 and the general considerations on the mathematical treatment of single molecule trajectories presented by Flomenbom3. Our study of single liposomes is also relevant to experiments involving proteins and liposomes, such as the enzyme experiments described in the review by Jørgensen and Hatzakis.4
Future of technology in NERC data models and informatics: outputs from InformaTEC
Authors: Kingdon Andrew , Giles Jeremy R. A. , Lowndes Jonathan P. 
Published: September 2014

Abstract
The ‘Big Data’ paradigm will revolutionize understanding of the natural environment. New technologies are revolutionizing our ability to measure, model, understand and make robust, evidence-based predictions at increasingly spatial and temporal resolutions. Realising this potential will require reengineering of environmental sciences in the observation infrastructure, in data management and processing, and in the culture of environmental sciences. Collectively these will deliver vibrant, integrated research communities. Manipulating such enormous data streams requires a new data infrastructure underpinned by four technologies. Pervasive environmental sensor networks will continuously measure suites of environmental parameters and transmit these wirelessly to scientists, regulators and modellers in real time. Integrated environmental modelling will process data, streamed from sensor networks, using components synthesizing natural systems developed by domain experts, each of which will be linked at runtime to other expert developed components. Semantic interoperability will facilitate cross-disciplinary working, as has already happened within the biosciences so that data items can be exchanged with unambiguous, shared meaning. Cloud computing will revolutionize data processing allowing scalable computing close to observations on an as-needed basis. Leveraging the full potential of these technologies requires a major culture change in the environmental sciences where national and continental scale observatories of sensors networks become basic scientific tools.
Redefining the tectonostratigraphic and structural architecture of the Almora klippe and the Ramgarh–Munsiari thrust sheet in NW India
Authors: Mandal S. , Robinson D. M. , Khanal S. , Das O. 
Published: September 2014

Abstract

We integrate U–Pb zircon geochronology and ε
Nd
(0) values with field mapping to determine which tectonostratigraphic units are represented to the north, south and within the Almora klippe in Kumaun, NW India. Rock in the Almora klippe and north of the Main Central thrust (MCT) have Neoproterozoic (
c.
900 Ma) detrital zircon ages, coupled with similar ε
Nd
(0) (−7.6 to −11.8) values, suggesting that these two units are the same tectonostratigraphic unit, and that the Almora klippe is the southern continuation of the MCT or another thrust in the Greater Himalayan thrust system. However, north of the Almora klippe, detrital zircon age populations establish the presence of Palaeoproterozoic rock instead of the previous interpretation of Neoproterozoic rocks. These Palaeoproterozoic Lesser Himalayan (LH) rocks are carried by the Ramgarh–Munsiari thrust (RMT) dipping south and folded underneath the klippe. South of the klippe, the RMT carries both the less metamorphosed Palaeoproterozoic and Neoproterozoic LH rocks, in disagreement with the idea that only Neoproterozoic–Cambrian LH rocks are present south of Almora klippe. These results suggest that previous cross-sections in Kumaun are incorrect and must be re-evaluated.

Supplementary material:

U–Pb zircon geochronological data table is available at
http://www.geolsoc.org.uk/SUP18777
.
Calreticulin Promotes Migration and Invasion of Esophageal Cancer Cells by Upregulating Neuropilin-1 Expression via STAT5A
Authors: Shi Feng , Shang Li , Pan Bei-Qing , Wang Xiao-Min , Jiang Yan-Yi , Hao Jia-Jie , Zhang Yu , Cai Yan , Xu Xin , Zhan Qi-Min , Wang Ming-Rong 
Published: September 2014

Abstract
Purpose: We previously revealed that the calreticulin (CRT) gene is a candidate oncogene promoting cell migration and invasion and that neuropilin-1 (NRP1) is a possible effector downstream of CRT in esophageal squamous carcinoma cells. This study aims to explore the mechanisms underlying the migration and invasion of esophageal cancer cells regulated by CRT through NRP1.
Experimental Design: Quantitative reverse-transcription polymerase chain reaction, Western blot analysis, chromatin immunoprecipitation, and reporter gene assays were used to investigate the relationship between CRT and NRP1. In vitro and in vivo assays were carried out to evaluate the effects of NRP1 on malignant phenotypes of ESCC cells and tumor metastasis in NOD/SCID mice. Immunohistochemistry was performed to analyze the expression of CRT and NRP1 in esophageal squamous cell carcinomas (ESCC).
Results: Knockdown of CRT decreased the expression of NRP1. Inhibition of NRP1 reduced ESCC cell motility in vitro and experimental metastasis in vivo. Ectopic expression of NRP1 rescued the defects of cell migration and invasion in CRT-shRNA cells. CRT depletion inhibited STAT5A phosphorylation at the Y694 site via a CaMKII-independent pathway. Moreover, STAT5A directly regulated NRP1 transcription. Knockdown of CRT or NRP1 led to a downregulation of MMP2, MMP9, and FAK. Notably, positive correlation was found between CRT and NRP1 expression in ESCC tissues (P = 5.87 × 10−5). CRT and NRP1 coexpression was significantly associated with lymph node metastasis (P = 0.025).
Conclusions: Our findings suggest that NRP1 is a critical downstream effector of CRT in promoting cell migration and invasion, which might contribute to the metastasis of ESCC. Clin Cancer Res; 20(23); 6153–62. ©2014 AACR.
A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
Authors: Messersmith Wells A. , Shapiro Geoffrey I. , Cleary James M. , Jimeno Antonio , Dasari Arvind , Huang Bo , Shaik M. Naveed , Cesari Rossano , Zheng Xianxian , Reynolds Jennifer M. , English Patricia A. , McLachlan Karen R. , Kern Kenneth A. , LoRusso Patricia M. 
Published: September 2014

Abstract
Purpose: To estimate the maximum tolerated dose (MTD) for continuous oral administration of the γ-secretase inhibitor PF-03084014, determine the recommended phase II dose (RP2D), and evaluate safety and preliminary activity in patients with advanced solid tumors.
Experimental Design: This open-label, phase I study consisted of a dose-finding portion based on a 3+3 design, followed by an expansion cohort. PF-03084014 was administered orally, twice daily (BID) for 21 continuous days. Tested doses ranged from 20 to 330 mg BID. In the expansion cohort, patients were to receive the estimated MTD or a lower dose of PF-03084014.
Results: A total of 64 patients received treatment. The MTD was estimated to be 220 mg BID. The RP2D was determined to be 150 mg BID, based on the better safety profile versus the 220-mg BID dose, given comparable NOTCH-related target inhibition. The most common treatment-related adverse events were diarrhea, nausea, fatigue, hypophosphatemia, vomiting, rash, and decreased appetite, which were generally mild to moderate in severity. One patient with advanced thyroid cancer had a complete response, and five of seven response-evaluable patients with desmoid tumor achieved a partial response (71.4% objective response rate). Tumor responses were mostly durable, ranging from 1.74+ to 24+ months. PF-03084014 demonstrated a generally dose-dependent pharmacokinetic profile at doses ranging from 20 to 330 mg BID. Consistent downmodulation of NOTCH-related HES4 gene expression was observed in peripheral blood from all evaluable patients.
Conclusion: Further development of PF-03084014 for the treatment of patients with advanced solid tumors is warranted and currently under evaluation. Clin Cancer Res; 21(1); 60–67. ©2014 AACR.
See related commentary by Hughes et al., p. 7
Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Authors: Oberthuer André , Juraeva Dilafruz , Hero Barbara , Volland Ruth , Sterz Carolina , Schmidt Rene , Faldum Andreas , Kahlert Yvonne , Engesser Anne , Asgharzadeh Shahab , Seeger Robert , Ohira Miki , Nakagawara Akira , Scaruffi Paola , Tonini Gian Paolo , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun , Vandesompele Jo , Speleman Frank , Noguera Rosa , Piqueras Marta , Bénard Jean , Valent Alexander , Avigad Smadar , Yaniv Isaac , Grundy Richard G. , Ortmann Monika , Shao Chunxuan , Schwab Manfred , Eils Roland , Simon Thorsten , Theissen Jessica , Berthold Frank , Westermann Frank , Brors Benedikt , Fischer Matthias 
Published: September 2014

Abstract
Purpose: To optimize neuroblastoma treatment stratification, we aimed at developing a novel risk estimation system by integrating gene expression–based classification and established prognostic markers.
Experimental Design: Gene expression profiles were generated from 709 neuroblastoma specimens using customized 4 × 44 K microarrays. Classification models were built using 75 tumors with contrasting courses of disease. Validation was performed in an independent test set (n = 634) by Kaplan–Meier estimates and Cox regression analyses.
Results: The best-performing classifier predicted patient outcome with an accuracy of 0.95 (sensitivity, 0.93; specificity, 0.97) in the validation cohort. The highest potential clinical value of this predictor was observed for current low-risk patients [5-year event-free survival (EFS), 0.84 ± 0.02 vs. 0.29 ± 0.10; 5-year overall survival (OS), 0.99 ± 0.01 vs. 0.76 ± 0.11; both P &lt; 0.001] and intermediate-risk patients (5-year EFS, 0.88 ± 0.06 vs. 0.41 ± 0.10; 5-year OS, 1.0 vs. 0.70 ± 0.09; both P &lt; 0.001). In multivariate Cox regression models for low-risk/intermediate-risk patients, the classifier outperformed risk assessment of the current German trial NB2004 [EFS: hazard ratio (HR), 5.07; 95% confidence interval (CI), 3.20–8.02; OS: HR, 25.54; 95% CI, 8.40–77.66; both P &lt; 0.001]. On the basis of these findings, we propose to integrate the classifier into a revised risk stratification system for low-risk/intermediate-risk patients. According to this system, we identified novel subgroups with poor outcome (5-year EFS, 0.19 ± 0.08; 5-year OS, 0.59 ± 0.1), for whom we propose intensified treatment, and with beneficial outcome (5-year EFS, 0.87 ± 0.05; 5-year OS, 1.0), who may benefit from treatment de-escalation.
Conclusions: Combination of gene expression–based classification and established prognostic markers improves risk estimation of patients with low-risk/intermediate-risk neuroblastoma. We propose to implement our revised treatment stratification system in a prospective clinical trial. Clin Cancer Res; 21(8); 1904–15. ©2014 AACR.
See related commentary by Attiyeh and Maris, p. 1782
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
Authors: Blagden Sarah , Olmin Aurelius , Josephs Debra , Stavraka Chara , Zivi Andrea , Pinato David J. , Anthoney Alan , Decordova Shaun , Swales Karen , Riisnaes Ruth , Pope Lorna , Noguchi Kohei , Shiokawa Rie , Inatani Michiyasu , Prince Jenny , Jones Keith , Twelves Chris , Spicer James , Banerji Udai 
Published: September 2014

AbstractPurpose: This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of CH5132799.Experimental Design: Patients with metastatic solid tumors were eligible for the study. CH5132799 was administered orally once daily or twice daily in 28-day cycles.Results: Thirty-eight patients with solid tumors received CH5132799 at 2 to 96 mg once daily or 48 to 72 mg twice daily. The MTD was 48 mg on the twice-daily schedule but was not reached on the once daily schedule. DLTs were grade 3 elevated liver function tests (LFT), grade 3 fatigue, grade 3 encephalopathy, grade 3 diarrhea, and grade 3 diarrhea with grade 3 stomatitis; all DLTs were reversible. Most drug-related adverse events were grade 1/2. Diarrhea (34%) and nausea (32%) were the most common events. Mean Cmax and AUC0-24 in steady state at MTD were 175 ng/mL and 1,550 ng·h/mL, respectively, consistent with efficacious exposure based on preclinical modeling. Reduction in SUVmax with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET) was observed in 5 of 7 patients at MTD. A patient with PIK3CA-mutated clear cell carcinoma of the ovary achieved a partial response by GCIG CA125 criteria and further, a heavily pretreated patient with triple-negative breast cancer had marked improvement in her cutaneous skin lesions lasting six cycles.Conclusion: CH5132799 is well tolerated at the MTD dose of 48 mg twice daily. At this dose, the drug had a favorable PK and PD profile and preliminary evidence of clinical activity. Clin Cancer Res; 20(23); 5908–17. ©2014 AACR.
Differential impact of unrecognised brain infarction on stroke outcome in non-valvular atrial fibrillation
Authors: Song Tae-Jin , Kim Jinkwon , Lee Hye Sun , Nam Chung Mo , Nam Hyo Seok , Kim Eun Hye , Lee Ki Jeong , Song Dongbeom , Heo Ji Hoe , Kim Young Dae 
Published: September 2014

SummaryThere has been little information regarding the impact of unrecognised brain infarctions (UBIs) on stroke outcome in patients with nonvalvular atrial fibrillation (NVAF). By using volumetric analysis of ischaemic lesions, we evaluated the potential impact of UBIs on clinical outcome according to their presence and categorised type. This study enrolled 631 patients with NVAF having no clinical stroke history. UBIs were categorised into three types as territorial, lacunar, or subcortical. We collected stroke severity, functional outcome at three months, and the total volume of UBIs and acute infarction lesions. We investigated the association between clinical outcome and the type or volume of UBI, using a linear mixed model and logistic regression analysis. UBIs were detected in 285 (45.2 %) patients; territorial UBIs were observed in 24.4 % of patients (154/631), lacunar UBIs in 25 % (158/631), and subcortical UBIs in 15.7 % (99/631). Although initial stroke severity was not different between patients with UBIs and those without, those with UBIs had less improvement during hospitalisation, leading to poorer outcome at three months. Among the three types of UBIs, only territorial UBIs were associated with poor outcome, especially in patients with relatively smaller acute infarction volume. UBIs, in particular, territorial UBIs, may be considered as predictors for poor outcome after ischaemic stroke in patients with NVAF. Our results suggest that the impact of UBIs on clinical outcome differs according to the type of UBIs and the acute stroke severity.